Atea Pharmaceuticals Inc Ordinary Shares AVIR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
-
Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
-
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026
-
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 80.20M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 3.28%
Company Profile
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 55
- Website
- https://www.ateapharma.com
Valuation
|
Metric
|
AVIR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.70 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
AVIR
Financial Strength
|
Metric
|
AVIR
|
|---|---|
Quick Ratio | 7.80 |
Current Ratio | 8.13 |
Interest Coverage | — |
Quick Ratio
AVIR
Profitability
|
Metric
|
AVIR
|
|---|---|
Return on Assets (Normalized) | −48.31% |
Return on Equity (Normalized) | −53.71% |
Return on Invested Capital (Normalized) | −57.62% |
Return on Assets
AVIR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!X>ft@ | LOCK|nqV@ | $127B | |||
| Moderna Inc
MRNA
| LOCK|>@z%%& | LOCK|!Gv | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|shw!jC | LOCK|gcW@ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|>d<DkJ! | LOCK|ks | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!fc^Jjr | LOCK|Ll | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Bb#hKh | LOCK|nKB>J | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|ntm&&kWW | LOCK|Dlq^ | $27B | |||
| Incyte Corp
INCY
| LOCK|y#&%q? | LOCK|<gg | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|ssF#%? | LOCK|^<z | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|#J^!x$ | LOCK|B$r | $14B |
United States